4.7 Article

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells

Journal

BLOOD
Volume 125, Issue 7, Pages 1061-1072

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2014-11-610436

Keywords

-

Categories

Funding

  1. Department of Pathology and Laboratory Medicine of Weill Cornell Medical College
  2. Tri-Institutional Training Program in Computational Biology and Medicine
  3. Brazilian Ministry of Higher Education Foundation CAPES (Coordination for the Improvement of Higher Education Personnel)
  4. Ministry of Health [RF 2010-2313979]
  5. Italian Association for Cancer Research [15835]
  6. Schwartz Family Research Fund
  7. Robert H. Lurie Comprehensive Cancer Center

Ask authors/readers for more resources

Classical Hodgkin lymphoma (cHL) is characterized by sparsely distributed Hodgkin and Reed-Sternberg (HRS) cells amid reactive host background, complicating the acquisition of neoplastic DNA without extensive background contamination. We overcame this limitation by using flow-sorted HRS and intratumor T cells and optimized low-input exome sequencing of 10 patient samples to reveal alterations in genes involved in antigen presentation, chromosome integrity, transcriptional regulation, and ubiquitination. beta-2-microglobulin (B2M) is the most commonly altered gene in HRS cells, with 7 of 10 cases having inactivating mutations that lead to loss of major histocompatibility complex class I (MHC-I) expression. Enforced wild-type B2M expression in a cHL cell line restored MHC-I expression. In an extended cohort of 145 patients, the absence of B2M protein in the HRS cells was associated with lower stage of disease, younger age at diagnosis, and better overall and progression-free survival. B2M-deficient cases encompassed most of the nodular sclerosis subtype cases and only a minority of mixed cellularity cases, suggesting that B2M deficiency determines the tumor microenvironment and may define a major subset of cHL that has more uniform clinical and morphologic features. In addition, we report previously unknown genetic alterations that may render selected patients sensitive to specific targeted therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available